drugset / Trial / NCT04936997

Immune Response to the COVID-19 Vaccine

NCT04936997

Phase 0 Completed 20 enrolled University of Arizona
NaSingle-groupOpen-labelTreatment

Summary

Explore the effects on immune response to include a potential third vaccine for the cancer cohort.

Timeline

Start
2021-06-07
Primary completion
2021-08-25
Completion
2022-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject BNT162b2 Messenger RNA (mRNA)

Indications